Bright Minds定价1.75亿美元股票发行

2026-01-08 15:29

Bright Minds Biosciences (DRUG) priced its previously announced public offering of ~1.95M shares at a price of $90.00 per share.
Gross proceeds are expected to be ~$175M.
The underwriters have a 30-day option to purchase up to an additional 291,750 shares.
The net proceeds will be used to fund future clinical trials for the company’s drug candidates, including for absence seizures, DEE, and Prader-Willi Syndrome, as well as initiation of phase 1 clinical drug trials for BMB-105, and additional research and development work on earlier phase programs, as well as for general corporate and working capital purposes.
The closing of the offering is expected to occur on January 9, 2026.
The stock price traded ~1% lower on Thursday during pre-market hours of trading.

More on Bright Minds Biosciences